Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | PKM | P14618 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9899326 | 0.84 | CRHR1 (0.39) | HCRTR1HCRTR2OPRK1 | |
| SCHEMBL1119706 | 0.84 | HCRTR1 (0.38) | HCRTR1HCRTR2SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL6523847 | 0.81 | NPC1 (0.41) | HCRTR1HCRTR2NPC1RAB9A | |
| SCHEMBL1598038 | 0.80 | IDO1 (0.49) | NPC1SMN1; SMN2ALDH1A1RAB9APKM | |
| SCHEMBL17141620 | 0.74 | NPC1 (0.48) | NPC1SMN1; SMN2ALDH1A1ATMKDM4E | |
| SCHEMBL9898617 | 0.72 | IL1B (0.42) | HCRTR1HCRTR2 | |
| SCHEMBL9928405 | 0.70 | MAPK1 (0.46) | HCRTR1HCRTR2ALDH1A1MAPK1GAA | |
| SCHEMBL10208455 | 0.70 | NPC1 (0.55) | NPC1SMN1; SMN2ALDH1A1ATMKDM4E | |
| SCHEMBL4303727 | 0.69 | HCRTR2 (0.64) | HCRTR1HCRTR2OPRK1NPC1SMN1; SMN2 | |
| SCHEMBL9900511 | 0.68 | HCRTR1 (0.37) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053979-A1 | PYRIDINE DERIVATIVES USED TO TREAT OREXIN RELATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20110053979-A1 | PYRIDINE DERIVATIVES USED TO TREAT OREXIN RELATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20110053979-A1 | PYRIDINE DERIVATIVES USED TO TREAT OREXIN RELATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| WO-2009124956-A1 | PYRIDINE DERIVATIVES USED TO TREAT OREXIN RELATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053979-A1 | PYRIDINE DERIVATIVES USED TO TREAT OREXIN RELATED DISORDERS | HCRTR2, HCRTR1, NPY4R | HCRTR1 2/4885HCRTR2 1/4885OPRK1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.